The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in cancer as a result of
genetic (eg, amplifications, mutations, deletions) and epigenetic (eg, methylation, regulation …

The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in human cancer and
represents an attractive target for therapies based on small molecule inhibitors. PI3K …

The phosphoinositide 3-kinase (PI3K) signaling pathway is significantly altered in a wide
variety of human cancers, driving cancer cell growth and survival. Consequently, a large …

In contrast with cytotoxic agents that do not differentiate between normal proliferating and
tumour cells, targeted therapies primarily exert their actions in cancer cells. Initiation and …

The PI3-kinase/AKT pathway integrates signals from external cellular stimuli to regulate
essential cellular functions, and is frequently aberrantly activated in human cancers. Recent …

In cancer, genetically activated proto-oncogenes often induce “upstream” dependency on
the activity of the mutant oncoprotein. Therapeutic inhibition of these activated oncoproteins …

Introduction: The PI3K signaling pathway is involved in the regulation of cancer cell growth,
motility, survival and metabolism. The pathway is frequently active in many different types of …

The PI3K pathway plays an important role in key cellular functions such as cell growth,
proliferation and survival. Genetic and epigenetic alterations in different pathway …

Evolving studies with several different targeted therapeutic agents are demonstrating that
patients with genomic alterations of the target, including amplification, translocation and …

Abstract The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated
pathways in cancer and, consequently, more than 40 compounds that target key …